At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 182 enrolled
Drug / intervention
LEO 90100 foam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris
In Brief
A Phase 3 clinical trial evaluating LEO 90100 foam and Dovobet® ointment for Psoriasis Vulgaris. Completed, enrolled 182 participants across 16 sites.
Detailed Summary
Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartJan 2019
Primary CompletionJun 2019
TodayJul 2026
First PostedJan 16, 2019
Enrollment StartJan 24, 2019
Primary CompletionJun 10, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.5 years ago
Interventions
LEO 90100 foamdrug
Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
Dovobet® ointmentdrug
Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.